000			01618 a2200445 4500
005			20250516051841.0
264		0	_c20120223
008			201202s 0 0 eng d
022			_a1740-7753
024	7		_a10.1177/1740774511407939 _2doi
040			_aNLM _beng _cNLM
100	1		_aRidker, Paul M
245	0	0	_aA tale of three labels: translating the JUPITER trial data into regulatory claims. _h[electronic resource]
260			_bClinical trials (London, England) _cAug 2011
300			_a417-22 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aCanada
650	0	4	_aCardiovascular Diseases _xprevention & control
650	0	4	_aDrug Labeling _xlegislation & jurisprudence
650	0	4	_aDrug and Narcotic Control
650	0	4	_aEurope
650	0	4	_aFemale
650	0	4	_aFluorobenzenes _xtherapeutic use
650	0	4	_aGovernment Regulation
650	0	4	_aHumans
650	0	4	_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xtherapeutic use
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPyrimidines _xtherapeutic use
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aRosuvastatin Calcium
650	0	4	_aSulfonamides _xtherapeutic use
650	0	4	_aTranslational Research, Biomedical
650	0	4	_aUnited States
650	0	4	_aUnited States Food and Drug Administration
773	0		_tClinical trials (London, England) _gvol. 8 _gno. 4 _gp. 417-22
856	4	0	_uhttps://doi.org/10.1177/1740774511407939 _zAvailable from publisher's website
999			_c21080220 _d21080220